Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels

Share Article

Proove Biosciences has developed a method to analyze a patient’s pain tolerance through genetic testing

We are tremendously excited to begin utilizing our research to help fill the knowledge gap between genetics and patient’s pain perception with the Proove Pain Perception Test - Brian Meshkin, CEO, Proove Biosciences

Proove Biosciences, the commercial and research leader in personalized medicine, is excited to announce a new genetic test built upon research from their published P.A.I.N. Study. The Proove Pain Perception Test will provide physicians with an objective way to understand theirs patient’s pain and why pain tolerance levels are stratified between individuals. With this new test, physicians will be able to identify whether a person has a genetic predisposition that will affect their pain tolerance.

The P.A.I.N. Study, which has been featured in U.S. News, Medscape and more, was conducted in order to objectively evaluate whether a chronic pain patient’s genotype determines their perception of pain. The IRB-approved cross-sectional study involved 2,721 subjects across 48 U.S. clinics. Subjects diagnosed with chronic pain and currently taking opioid medications were genotyped, and specific ranges of single nucleotide polymorphisms were evaluated. Patients then completed a Pain VAS rating their pain perception on a scale of 1 to 10.

Statistical significance was found among all four assessed variants to help objectively stratify pain perception. Specifically, the DRD1 variant was more prevalent in the low pain perception population compared to the high pain perception population; COMT and OPRK variants were more prevalent among the moderate population, compared to those with high pain perception; and DRD2 was more prevalent among the high pain perception population than the moderate population. The analysis provided a more objective method to define subjective Pain VAS perceptions.

“Chronic pain can affect every other part of life, which is why it is so critically important to analyze a patient’s genes to better understand how that individual perceives pain,” stated Brian Meshkin, founder and CEO of Proove Biosciences. “We are tremendously excited to begin utilizing our research to help fill the knowledge gap between genetics and patient’s pain perception with the Proove Pain Perception Test.”

About Proove Biosciences

Our mission is to change the future of medicine by providing proof to improve healthcare decisions. We envision a future when clinicians will know how patients are likely to respond to medications before writing a prescription. We believe genetic testing can provide such knowledge: Using a simple cheek swab, Proove performs proprietary genetic tests in its CLIA-certified laboratory. Healthcare providers use the results to evaluate how their patients will metabolize medications, and to screen for the likelihood of medication misuse.

Founded in 2009 with offices in Southern California and the Baltimore-Washington metropolitan area, Proove Biosciences is the leader in genetics-related personalized pain medicine research with hundreds of clinical research sites across the U.S. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nicole McMillan
Proove Biosciences
+1 855-776-6832 Ext: 716
Email >
@proovebio
Follow >
Proove Biosciences, Inc.
since: 01/2012
Like >